Cancer Genome Landscapes
By Bert Vogelstein, N. Papadopoulos, Victor E. Velculescu, Shibin Zhou, L. Diaz, Kenneth W. Kinzler. Science, 2013
7,218 citations recorded by the source corpus.
Over the past decade, comprehensive sequencing efforts have revealed the genomic landscapes of common forms of human cancer. For most cancer types, this landscape consists of a small number of “mountains” (genes altered in a high percentage of tumors) and a much larger number of “hills” (genes altered infrequently). To date, these studies have revealed ~140 genes that, when altered by intragenic mutations, can promote or “drive” tumorigenesis. A typical tumor contains two to eight of these “driver gene” mutations; the remaining mutations are passengers that confer no selective growth advantage. Driver genes can be classified into 12 signaling pathways that regulate three core cellular processes: cell fate, cell survival, and genome maintenance. A better understanding of these pathways is one of the most pressing needs in basic cancer research. Even now, however, our knowledge of cancer genomes is sufficient to guide the development of more effective approaches for reducing cancer morbidity and mortality.
Subfields: Cancer Research, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/65f1b5e127080e1050a96a8303517ac386064f65
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
- Gad Getz
- A. Bardelli
- V. Plaks
- Zena Werb
- David C. Wedge
- Elaine R. Mardis
- Niwen Kong
- Niko Beerenwinkel
In Molecular Biology
- Manel Esteller
- Peter A. Jones
- S. Baylin
- Trey Ideker
- Peter W. Laird
- Richard A. Young
- Abhishek Niroula
- Hans Clevers
Citations in the corpus
- Signal transduction in cancer. (2015, neutral): “” Typically only two to eight are the “driver mutations” that cause progression of the cancer (Vogelstein et al. 2013).”
- MOLI: multi-omics late integration with deep neural networks for drug response prediction (2019, background): “However, inreality, themajorityofthesegenomicalterationsseemtohavenoimpact on cancer development (Vogelstein et al. , 2013) and might appear just by chance.”
- Revisiting the hallmarks of cancer. (2017, neutral): “pancreatic adenocarcinoma) could carry driving mutation(s) in the labeled oncogene compartment alone [16].”
- The emerging complexity of gene fusions in cancer (2015, background): “Promoter swapping between the genes for a novel zinc finger protein and β-catenin in pleiomorphic adenomas with t(3;8)(p21;q12) translocations.”
- FunSeq2: a framework for prioritizing noncoding regulatory variants in cancer (2014, background): “Cancer driver genes are the union of genes from Vogelstein et al ., cancer gene consensus, and COS-MIC [2,41,42].”
- Evaluation of in silico algorithms for use with ACMG/AMP clinical variant interpretation guidelines (2017, background): “TSG variants: this dataset consists of 502 benign and 532 pathogenic variants in TSGs as defined by genes having a high TSG score and a low oncogene score as described in [29].”